Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Kenacort to prevent refractory anastomotic strictures after esophageal atresia repair
2022-003287-25Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of triamcinolone in esophageal atresia (EA) and anastomotic esophageal stricture (2 arms), sponsored by Erasmus MC. Primary endpoint: Total number of dilatations. Started Feb 2023; status: active.
02
Drugs
triamcinolone
03
Conditions
esophageal atresia (EA)anastomotic esophageal stricture
Beyond the preview
Go deeper on 2022-003287-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003287-25.